CONDENSED CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions	Jun. 30, 2025	Dec. 31, 2024
Current Assets
Cash and cash equivalents	$ 8,007	$ 13,242
Short-term investments	615	447
Accounts receivable (net of allowance for doubtful accounts of $94 in 2025 and $89 in 2024)	11,846	10,278
Inventories (excludes inventories of $4,882 in 2025 and $4,193 in 2024 classified in Other assets - see Note 6)	6,601	6,109
Other current assets	9,996	8,706
Total current assets	37,065	38,782
Investments	774	463
Property, Plant and Equipment, at cost, net of accumulated depreciation of $20,256 in 2025 and $19,155 in 2024	25,236	23,779
Goodwill	21,591	21,668
Other Intangibles, Net	15,193	16,370
Other Assets	17,664	16,044
Total Assets	117,523	117,106
Current Liabilities
Loans payable and current portion of long-term debt	1,434	2,649
Trade accounts payable	3,892	4,079
Accrued and other current liabilities	14,502	15,694
Income taxes payable	4,156	3,914
Dividends payable	2,053	2,084
Total current liabilities	26,037	28,420
Long-Term Debt	33,968	34,462
Deferred Income Taxes	1,427	1,387
Other Noncurrent Liabilities	7,031	6,465
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2025 and 2024	1,788	1,788
Other paid-in capital	44,644	44,704
Retained earnings	68,477	63,069
Accumulated other comprehensive loss	(5,421)	(4,945)
Stockholders' equity before deduction for treasury stock	109,488	104,616
Less treasury stock, at cost: 1,073,963,194 shares in 2025 and 1,049,466,187 shares in 2024	60,495	58,303
Total Merck & Co., Inc. stockholders’ equity	48,993	46,313
Noncontrolling Interests	67	59
Total equity	49,060	46,372
Liabilities and Equity	$ 117,523	$ 117,106